Leukocyte adhesion deficiency type III (LAD-III) is a rare, inherited disorder that affects the body's ability to fight infections. It is caused by mutations in the ITGB2 gene, which is responsible for producing a protein called integrin beta-2. This protein helps white blood cells (leukocytes) stick to the walls of blood vessels, which is necessary for them to travel to the site of an infection. People with LAD-III have a reduced ability to fight infections, and they may experience recurrent bacterial infections, delayed wound healing, and other complications.

The symptoms of Leukocyte adhesion deficiency type III (LAD-III) include recurrent bacterial infections, especially of the skin, lungs, and gastrointestinal tract. Other symptoms may include delayed growth, poor wound healing, and recurrent fever.

Leukocyte adhesion deficiency type III (LAD-III) is a rare, inherited disorder caused by mutations in the ITGB2 gene. This gene provides instructions for making a protein called integrin beta-2, which is found on the surface of white blood cells called leukocytes. This protein helps leukocytes stick to other cells and to the walls of blood vessels, a process known as adhesion. Mutations in the ITGB2 gene reduce or eliminate the production of integrin beta-2, which prevents leukocytes from adhering to other cells and the walls of blood vessels. As a result, leukocytes are unable to move to the sites of infection, leading to recurrent and severe bacterial infections.

1. Hematopoietic stem cell transplantation (HSCT): HSCT is the only curative treatment for Leukocyte adhesion deficiency type III. It involves replacing the defective stem cells with healthy ones from a donor.

2. Antibiotic therapy: Antibiotics can be used to treat infections caused by Leukocyte adhesion deficiency type III.

3. Immunoglobulin therapy: Immunoglobulin therapy can be used to help boost the immune system and reduce the risk of infection.

4. Bone marrow transplantation: Bone marrow transplantation is another option for treating Leukocyte adhesion deficiency type III. It involves replacing the defective stem cells with healthy ones from a donor.

5. Gene therapy: Gene therapy is a potential treatment for Leukocyte adhesion deficiency type III. It involves

1. Genetic mutation: Leukocyte adhesion deficiency type III is caused by a genetic mutation in the ITGB2 gene.

2. Family history: Individuals with a family history of Leukocyte adhesion deficiency type III are at an increased risk of developing the condition.

3. Age: Leukocyte adhesion deficiency type III is more common in infants and young children.

At this time, there is no known cure for Leukocyte adhesion deficiency type III. However, there are medications that can help manage the symptoms. These include antibiotics to treat infections, immunoglobulin replacement therapy to help boost the immune system, and anti-inflammatory medications to reduce inflammation.